• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Dithiothreitol (DTT)-based Method Validated for Blood Compatibility Testing in Patients Taking Daratumumab

September 14, 2016

Blood testing

Daratumumab (DARA), an immunoglobulin that targets CD38 on myeloma cells, was recently approved by the U.S. FDA. DARA, however, also binds to CD38 on red blood cells (RBCs), which interferes with blood compatibility testing if the patient also needs a blood product.  While DARA does not affect ABO/RhD typing, positive agglutination reactions occur in indirect antiglobulin tests, antibody detection panels, and antihuman globulin crossmatches in all types of media.  A new method using dithiothreitol (DTT) has been described to inhibit DARA interference by denaturing cell surface CD38 on RBCs. In order to validate this new method, 25 blood bank laboratories in North and South America, Europe and Asia Pacific were given paired plasma samples: one sample contained DARA and the second sample contained DARA plus a clinically relevant antibody (anti-D, anti-Fya or anti-s).  By using DTT, all 25 laboratories were able to distinguish DARA interference and detect the unknown antibody with all testing methods (gel, tube or solid phase).  By using DTT, blood service labs may provide safe blood products to patients taking DARA.

Reference:

  1. Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, Fung MK, Unger M, Doshi P, Murphy MF, Dumont LJ, Kaufman RM, Collaborative D-DSGftB. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion 2016.

Filed Under

  • News
  • Quality Control and Regulatory
  • Serology/Genotyping

Recommended

  • Transfusing Individuals with Asian-type DEL Rh Antigen

  • Aspirin Increases Bleeding Risk

  • Frequent Whole Blood Donations Not Associated with Cardiovascular Disease

Show Comments

Reader Interactions

Comments

  1. Lene Gustafsson says

    September 20, 2016 at 6:49 am

    For how long time (hour/Days) can you store and use the DTT-treated RBC for screening or identification?

  2. Helen Carpenter says

    October 18, 2016 at 8:40 am

    We antigen typed DTT treated panel cells every other day for 2 weeks and the antigen strength was not affected. During the testing we washed the cells before antigen typing. When we let the treated cells sit for more than 4-5 days without washing them they hemolyzed. So our experience is that if you wash them every other day you can use them up to 2 weeks. We tested for all clinically significant antigens.

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley